Hanson & Doremus Investment Management Acquires 2,180 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Hanson & Doremus Investment Management increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 28.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,775 shares of the medical research company’s stock after buying an additional 2,180 shares during the period. Hanson & Doremus Investment Management’s holdings in IQVIA were worth $1,921,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Capital Performance Advisors LLP bought a new stake in shares of IQVIA during the 3rd quarter valued at $27,000. Park Place Capital Corp bought a new stake in shares of IQVIA during the third quarter valued at about $28,000. Avior Wealth Management LLC boosted its holdings in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. boosted its stake in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares during the period. Finally, UMB Bank n.a. grew its holdings in shares of IQVIA by 74.4% during the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after purchasing an additional 99 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on IQV shares. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th. Barclays cut their price objective on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. BTIG Research lowered their price target on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft reduced their price objective on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Morgan Stanley lowered their target price on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $255.71.

IQVIA Trading Down 2.7 %

Shares of IQV opened at $197.90 on Thursday. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The firm has a market capitalization of $35.92 billion, a price-to-earnings ratio of 25.97, a PEG ratio of 2.14 and a beta of 1.48. The firm’s 50-day moving average price is $200.27 and its 200-day moving average price is $220.95. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.